APRE Stock — Aprea Therapeutics Inc.: Cash, EV, Pipeline

Share price

$0.76

Market cap

$9.6M

Cash

$41.2M

Enterprise value

-$31.6M

Balance sheet

Cash	$41.2M
Debt	$0.0M
Net cash	$41.2M
Enterprise value	-$31.6M
Basic shares	12.4M shares
Fully diluted shares	20.5M shares
Fully diluted market cap	$15.6M
Cash per share	$3.32

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading APRE daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jul 13 - Aug 24	APR-1051	Phase 1	Advanced Solid Tumor	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

APR-1051

Phase 1 · Active Modality: oral small-molecule WEE1 kinase inhibitor

Target WEE1

Indications

biomarker-defined cancers (Phase 1)

Status note Phase 1 ACESOT-1051 dose-escalation study ongoing; lead clinical program; no discontinuation disclosed.

ATRN-119

Phase 1 · Active Modality: oral macrocyclic small-molecule ATR inhibitor

Target ATR

Indications

advanced solid tumors (Phase 1)
hematologic malignancies (potential combinations) (Phase 1)

Status note ABOYA-119 Phase 1/2a study closed after RP2D determination; company exploring investigator-initiated combination studies; no discontinuation disclosed.

DYRK1A/B inhibitor

Preclinical · Active Modality: macrocyclic small-molecule DYRK1A/B inhibitor

Target DYRK1A/B

Indications

not disclosed (Preclinical)

Catalysts

— Q4 2026

Status note Early-stage program; IND-enabling studies potentially in Q4 2026 subject to resources.

APR-246

Stage not disclosed · Active Modality: reactivator of mutant p53

Target mutant p53

Indications

not disclosed (Stage not disclosed)

Status note No ongoing clinical trials; no discontinuation disclosed.

Per-asset detail extracted from the 10-Q filed 2026-08-12. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	APR-1051
Lead indication	Advanced Solid Tumor
Lead phase	Phase 1
Active trials	1
Collaborator trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06260514	Phase 1	Recruiting	Sponsor	Aprea Therapeutics	—	Advanced Solid Tumor	—
NCT07578467	Phase 1/2	Not yet recruiting	Collaborator	Abramson Cancer Center at Penn Medicine	—	HPV Positive Oropharyngeal Squamous Cell Carcinoma; Squamous Cell Carcinoma; HPV (Human Papillomavirus)-Associated Carcinoma	—
NCT07617363	Phase 1	Not yet recruiting	Collaborator	Washington University School of Medicine	—	Acute Myeloid Leukemia; High-risk Myelodysplastic Syndrome	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 2 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 3 active trials for Aprea Therapeutics on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Sphera Biotech	270,000	no change	0.03%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

APRE — Aprea Therapeutics Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Institutional holders